"name","description","label","instanceType","uuid:ID","rationale","id"
"Study Design 1","The main design for the study","","StudyDesign","c7989daf-597d-4f88-b23c-6a7027a6b1e8","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign_1"
